Second source of growth quietly turning on: management is adding a new way to grow that does not require winning new dem
The model's full reasoning — Q2 2021 call → NOWe need to determine if management describes a new way to grow that does not depend on persuading new customers to buy, but rather from something already inside the company, and that it is already beginning to work in the current period. Let's analyze the transcript. Key points: - Revenue growth from Firdapse sales, but that's from new patients and existing patients. However, there is mention of "stable discontinuation rates" and "low 90-day discontinuation rates of less than 15%". Also "discontinuations were 25% lower than the first half of 2020". That suggests they are retaining more patients, which is a form of growth from existing customers (reducing churn). But is that described as a new way to grow? They mention it as part of commercial execution. They also mention "favorable reimbursement dynamics" and "prescription approval rates over 90%". But the main growth is from new patient enrollments. - They also have a licensing agreement with DyDo for Japan, which contributed $2.7 million in revenue. That's a one-time upfront payment? Actually, it's revenue from a license agreement. That is not recurring growth from existing customers; it's a new deal. - They mention "expanding our global footprint" and "affordable access" in Canada. But that's about new markets. - They talk about "long-acting Firdapse" development, but that's future. - They talk about "business development" and acquisitions, but that's future. - They mention "intellectual property" and patents, but that's about protecting franchise, not growth. - They mention "patient resources" to shorten diagnostic journey, which is about getting new patients. - They mention "discontinuation rates" being low and improving. That is about retaining existing patients. But is that described as a new way to grow? They say "stable discontinuation rates" and "discontinuations were 25% lower". That means they are losing fewer patients, so net growth is higher. But is that a "new way to grow" that they have recently gained? It seems like an ongoing operational metric, not a new strategy. - They also mention "favorable reimbursement dynamics" and "prescription approval rates over 90%". That might mean they are getting better reimbursement, which could be a form of price improvement? But they don't explicitly say they raised prices.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| IFS | Intercorp Financial Services Inc. | Q1 2024 | 2024-05-14 | C+ |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| BZUN | Baozun Inc. | Q2 2023 | 2023-08-28 | D |
| PTLO | Portillo's Inc. | Q2 2023 | 2023-08-05 | B |
| NMR | Nomura Holdings, Inc. | Q1 2024 | 2023-08-02 | D |
| GS | The Goldman Sachs Group, Inc. | Q2 2023 | 2023-07-19 | C+ |
| PFIE | Profire Energy, Inc. | Q1 2023 | 2023-05-13 | B |
| CARS | Cars.com Inc. | Q1 2023 | 2023-05-06 | B |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| ALGN | Align Technology, Inc. | Q4 2022 | 2023-02-01 | F |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| CCRN | Cross Country Healthcare, Inc. | Q1 2022 | 2022-05-04 | B |
| ARCC | Ares Capital Corporation | Q1 2022 | 2022-04-26 | B |
| CNXC | Concentrix Corporation | Q1 2022 | 2022-03-30 | B |
| VVV | Valvoline Inc. | Q1 2022 | 2022-02-09 | C+ |
| ZH | Zhihu Inc. | Q3 2021 | 2021-11-22 | D |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| CRS | Carpenter Technology Corporation | Q4 2021 | 2021-08-01 | A |
| TENB | Tenable Holdings, Inc. | Q2 2021 | 2021-07-27 | A |
| T | AT&T Inc. | Q3 2018 | 2018-10-24 | C+ |
| AU | AngloGold Ashanti's | Q2 2018 | 2018-08-20 | B |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| ROP | Roper Technologies, Inc. | Q2 2018 | 2018-07-26 | A |
| SATS | EchoStar Corporation | Q1 2018 | 2018-05-10 | C+ |
| BCOV | Brightcove Inc. | Q1 2018 | 2018-04-26 | B+ |
| TOUR | Tuniu Corporation | Q4 2017 | 2018-03-14 | D |
| MKTX | MarketAxess Holdings Inc. | Q3 2017 | 2017-10-25 | C+ |
| PTC | PTC Inc. | Q3 2017 | 2017-07-19 | C+ |
| ARKR | Ark Restaurants Corp. | Q1 2016 | 2016-05-13 | B |
| LBTYK | Liberty Global's | Q1 2016 | 2016-05-10 | C+ |
| RCL | Royal Caribbean Cruises Ltd. | Q1 2016 | 2016-04-29 | C+ |
| WK | Workiva Inc. | Q4 2015 | 2016-03-01 | B |
| SAN | Banco Santander, S.A. | Q4 2015 | 2016-01-27 | B |
MKTX · Q3 2017 → YESThe question is: Does management describe that the company has recently GAINED A NEW WAY TO GROW THAT DOES NOT DEPEND ON PERSUADING NEW CUSTOMERS TO BUY — something already inside its own walls, and i...YES The transcript shows management describing exactly this dynamic in open trading. Rick notes that “Open trading is increasingly becoming an important distribution channel for dealers and their efforts to increase trading velocity and reduce balance sheet usage,” and that “Our vast network of investors and dealers operating on the open trading platform provide an additive tool of liquidity for dealers to move bonds.” Dealer-initiated open trades hit a new high of 24 % of total volume, and open trading already accounts for 37 % of U.S. high-yield volume, 15 % of high-grade, and 13 % of emerging-market volume. These metrics are presented as current-quarter results (new record participation, 51 % rise in price responses, $56 billion traded, ADV +29 %, transactions +45 %), not as future plans. Management treats this as a meaningful, already-operating growth engine that runs on the company’s existing installed base of liquidity providers and clients rather than on winning new ones. The same logic appears in the micro-lot discussion, where the platform’s existing liquidity is already capturing 23 % share of sub-$250 k trades—greater than all other retail ATS platforms combined—without any new customer acquisition.
ZH · Q3 2021 → YESThe question is: Does management describe that the company has recently GAINED A NEW WAY TO GROW THAT DOES NOT DEPEND ON PERSUADING NEW CUSTOMERS TO BUY — something already inside its own walls, and i...YES The transcript shows management describing exactly this: the joint-creation feature (launched October) lets text creators authorize video creators to use their existing answers as video scripts and share copyrights, turning 1.8 million pieces of already-authorized content into new videos that drive millions of additional views and engagement. They present this 1.8 million figure and the resulting video metrics (e.g., 4 million-view and 2.59 million-view examples) as real, observable effects already occurring in Q3, not future plans. They tie it directly to higher video consumption penetration (37% of DAUs), creator income, and overall community monetization efficiency, framing it as a meaningful new growth engine that runs on the company’s existing content library and creator base rather than solely on acquiring new users. This is presented as already working and central to sustaining the 115% revenue growth and 110% paid-member growth. The answer is therefore YES.
CRS · Q4 2021 → YESThe question is: Does management describe that the company has recently GAINED A NEW WAY TO GROW THAT DOES NOT DEPEND ON PERSUADING NEW CUSTOMERS TO BUY — something already inside its own walls, and i...YES The transcript shows management describing the hot strip mill commissioning and Athens facility as already enabling new revenue streams from existing soft magnetics and aerospace capabilities (e.g., producing for FAA-certified motors and sensors), with these outputs explicitly tied to current-period activity rather than future plans. This represents an internal growth lever—leveraging 100% owned assets and approvals already in place—independent of acquiring new customers, and management presents it as actively contributing to the recovery narrative in the current quarter. While broader backlog and bookings reflect market demand, the specific mill and qualification details are framed as a fresh, self-contained growth mechanism now in operation.